Results 151 to 160 of about 3,282 (184)
Comparative Efficacy of Novel Versus Traditional Antiemetic Agents in Preventing Chemotherapy-Induced Nausea and Vomiting With Moderate or Highly Emetogenic Chemotherapy: A Systematic Review. [PDF]
CureusNashed SM +10 more
europepmc +1 more source
Comparison of aprepitant, dexamethasone, and ondansetron with dexamethasone and ondansetron for prevention of postoperative nausea and vomiting in high-risk patients undergoing laparoscopic surgeries: a randomized controlled trial in India. [PDF]
J Minim Invasive SurgBala S +5 more
europepmc +1 more source
Association of tongue diagnosis-guided acupuncture with postoperative nausea and vomiting in high-risk laparoscopic surgery patients. [PDF]
Am J Transl ResTan D +6 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2004
Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate ...
M Asif A, Siddiqui, Lesley J, Scott
+5 more sources
Palonosetron is a potent and highly selective serotonin 5-HT(3) receptor antagonist that has been evaluated for the prevention of chemotherapy-induced nausea and vomiting. black triangle Intravenously administered palonosetron has a linear pharmacokinetic profile, with a long terminal elimination half-life ( approximate, equals 40 hours) and moderate ...
M Asif A, Siddiqui, Lesley J, Scott
+5 more sources
Reactions Weekly, 2009
Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists. Intravenous palonosetron is widely indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in the acute and delayed phases following moderately emetogenic
Lily P H, Yang, Lesley J, Scott
openaire +3 more sources
Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists. Intravenous palonosetron is widely indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in the acute and delayed phases following moderately emetogenic
Lily P H, Yang, Lesley J, Scott
openaire +3 more sources
Acta Anaesthesiologica Belgica, 2020
Background : Postoperative nausea and vomiting (PONV) is one of the common complications after surgery. This randomized double-blind study was planned to compare the effectiveness of different antiemetic regimens for PONV prophylaxis in moderately high-risk patients.
N Bharti, N.B. Panda, K Kumari
openaire +1 more source
Background : Postoperative nausea and vomiting (PONV) is one of the common complications after surgery. This randomized double-blind study was planned to compare the effectiveness of different antiemetic regimens for PONV prophylaxis in moderately high-risk patients.
N Bharti, N.B. Panda, K Kumari
openaire +1 more source
Electrocardiographic findings of palonosetron in cancer patients
Supportive Care in Cancer, 2011Nausea and vomiting are among the major problems occurring during and after the chemotherapy treatments of cancer patients. The recently developed 5-HT(3) antagonists have proved much more effective than former agents. Several studies have shown that these agents cause certain ECG changes.
Gonullu, Guzin +4 more
openaire +3 more sources
Current opinion in investigational drugs (London, England : 2000), 2003
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002.
openaire +1 more source
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002.
openaire +1 more source